Literature DB >> 16998946

Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study.

L Wei1, T M MacDonald, A D Watson, M J Murphy.   

Abstract

BACKGROUND: There is considerable evidence that statins can reduce cardiovascular events. Currently high-risk patients are treated to a target cholesterol concentration. An alternative prescribing strategy (the 'fire-and-forget' approach) would instead deploy low-dose statins more widely. It has been suggested that for the same cost this approach might prevent more cardiovascular events. We have compared the treat-to-target and fire-and-forget statin prescribing strategies with respect to adherence and cardiovascular outcomes.
METHODS: We used a population-based record-linkage database containing several data sets linked by a unique patient identifier. We identified two cohorts of patients. Patients in the treat-to-target cohort were prescribed a statin, and subsequent measurement of their cholesterol was followed by upward titration of their statin dose if necessary. Patients in the fire-and-forget cohort were prescribed a statin, but no further cholesterol measurement was observed during the follow-up period.
FINDINGS: Adherence to statin treatment in patients treated to target was significantly better than in patients treated on a fire-and-forget basis (adjusted odds ratio 2.51, 95%CI 2.26-2.78). We found a lower cardiovascular disease (CVD) event rate in patients treated to target than in fire-and-forget patients (hazard ratio of CVD or cardiovascular death 0.41 (0.35-0.48) even after adjustment was made for adherence and baseline CVD risk).
INTERPRETATION: Our findings suggest that adherence to statins is worse in patients treated on a fire-and-forget basis than in patients treated to a target cholesterol concentration, and that this prescribing strategy is associated with worse cardiovascular outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16998946     DOI: 10.1002/pds.1297

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  8 in total

1.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

2.  In Reply.

Authors:  Klaus G Parhofer
Journal:  Dtsch Arztebl Int       Date:  2016-09-23       Impact factor: 5.594

3.  Familial hypercholesterolemia--screening to facilitate early prevention.

Authors:  Klaus G Parhofer
Journal:  Dtsch Arztebl Int       Date:  2014-08-04       Impact factor: 5.594

Review 4.  The Treatment of Disorders of Lipid Metabolism.

Authors:  Klaus G Parhofer
Journal:  Dtsch Arztebl Int       Date:  2016-04-15       Impact factor: 5.594

5.  Patients' perspectives on nonadherence to statin therapy: a focus-group study.

Authors:  Vicki Fung; Fiona Sinclair; Huihui Wang; Diane Dailey; John Hsu; Ruth Shaber
Journal:  Perm J       Date:  2010

Review 6.  Recognizing and improving patient nonadherence to statin therapy.

Authors:  Humayun J Chaudhry; Brian McDermott
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

7.  ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy.

Authors:  Carmine Riccio; Michele Massimo Gulizia; Furio Colivicchi; Andrea Di Lenarda; Giuseppe Musumeci; Pompilio Massimo Faggiano; Maurizio Giuseppe Abrignani; Roberta Rossini; Francesco Fattirolli; Serafina Valente; Gian Francesco Mureddu; Pier Luigi Temporelli; Zoran Olivari; Antonio Francesco Amico; Giancarlo Casolo; Claudio Fresco; Alberto Menozzi; Federico Nardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

8.  'Real-life' reduction in cholesterol with statins, 1993 to 2002.

Authors:  Michael J Murphy; Li Wei; Alexander D Watson; Thomas M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.